ChemRar High-Tech Center

ChemRar High-Tech Center is a unique pharma and biotechnology conglomerate built in Russian Federation by highly innovative life science R&D organizations, discovering, developing and commercializing novel drugs for partners in Russia and worldwide.

The mission of the company is to develop and commercialise existing drugs on the basis of novel “post-genomic” technologies used for treatment of cancer, infectious, cardiovascular and central nervous system (CNS) diseases as well metabolic disorders.

ChemRar performs a full cycle of pre-clinical and clinical research of new molecules including screening and identification of the essential biological targets for new molecules, synthesis and research of new molecules as well as full cycle of production.


Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s larg-est biotech company with truly differentiated medicines in oncology, virology, inflamma-tion, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personal-ized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2010, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D.

The Group posted sales of over 47.16 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

For more information:

Chemical Diversity Research Institute (CDRI)

CDRI is a contract research organization focused on pre-clinical and clinical R&D from target identification to clinical candidate nomination and Proof of Concept in human. CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSource™ platforms. Since 1990 we continue extending quality R&D services in CNS, oncology, inflammation, CV and metabolic disease area to the pharma and biotech partners.

CDRI’s collaboration network encompasses hundreds of scientific institutions and individual research groups in Russia, CIS countries and rest of the world. The Institute has established broad cooperation with the Moscow State University, Moscow Institute of Physics and Technology, D. Mendeleev University of Chemical Technology of Russia and other in science and education fields. CDRI offers internships, graduate and postdoctoral positions to young scientists, attracting returnees with US and European industrial experience thus enhancing the core basic and application sciences and pharmaceutical industrial expertise in Russian Federation.

For more information:

ChemDiv, Inc

ChemDiv is a global discovery and development organization headquartered in San Diego, CA, USA with subsidiaries in Russia, business and logistics operations around the world.

ChemDiv is a provider of integrated discovery and development solutions based on a strong chemistry platform. Integrated Discovery outSource™ solutions offered by ChemDiv cover the complete range of disciplines needed to bring a project in CNS, oncology, inflammation, metabolic and infectious disease area from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate ( Phase I and II).

For more information: